Keiran S.M. Smalley - Concepedia

Author

Keiran S.M. Smalley

Also Known As

Færgeman, Nils J., K S M Smalley, K S Smalley, K SMALLEY, K Smalley, K. S. M. Smalley, K. Smalley, K.S.M. Smalley, KEIRAN S. M. SMALLEY, KEIRAN S.M. SMALLEY

530

Publications

20K

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center The Wistar Institute Molecular Oncology (United States)University of Pennsylvania University of South Florida

About

Keiran S.M. Smalley is an author at Moffitt Cancer Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	41	3.3K
2	Health Sciences	3	3	66
3	Natural Sciences	3	3	78
4	Engineering	1	1	126
5	Biochemistry	1	1	16

Keiran S.M. Smalley

104

Publications

15.8K

Citations

H-Index

Page 1

	Year	Citations
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky, Kotb Abdelmohsen, Akihisa Abe, Autophagy	2016	5.9K
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity James Tsai, John Tayu Lee, Weiru Wang, Proceedings of the National Academy of Sciences	2008	1.3K
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression Kim H.T. Paraiso, Yun Xiang, Vito W. Rebecca, Cancer Research Cancer ResearchCell RegulationMedicineApoptosisPten Expression	2011	544
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Keiran S.M. Smalley, Nikolas K. Haass, Patricia Brafford, Molecular Cancer Therapeutics	2006	455
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy Kim H.T. Paraiso, Inna V. Fedorenko, Liliana Cantini, British Journal of Cancer	2010	309
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in <i>BRAF</i> V600E–mutated melanomas Keiran S.M. Smalley, Mercedes Lioni, Maurizia Dalla Palma, Molecular Cancer Therapeutics	2008	293
Rewired ERK-JNK Signaling Pathways in Melanoma Pablo Lopez‐Bergami, Conway C. Huang, James S. Goydos, Cancer Cell Signal TransductionSignaling PathwayReceptor Tyrosine KinaseMelanomaErk-jnk Signaling Pathways	2007	286
Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression Zhaojun Liu, Min Xiao, Klara Balint, Cancer Research	2006	271
Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885 Alastair J. King, Denis R. Patrick, Roberta S. Batorsky, Cancer Research PathologyOncogenic Braf AllelesTumor BiologyOncologyTumor Phenotype	2006	262
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel Nikolas K. Haass, Katrin Sproesser, Thiennga K. Nguyen, Clinical Cancer Research	2008	241

Page 1